ANI's Cortrophin guidance cut tempers a strong Q3 as Egetis deal pivots to rare disease

The quarter in numbers

ANI Pharmaceuticals reported third-quarter 2026 total net revenues of $290.8 million, up 27.6% from $227.8 million a year earlier. GAAP net income available to common shareholders was $35.1 million, or $1.51 per diluted share, against $26.3 million, or $1.13, in the prior-year quarter. Adjusted non-GAAP diluted EPS was $2.70 versus $2.04, and adjusted non-GAAP EBITDA rose 39.8% to $83.3 million. The company attributed the EBITDA gain to higher net revenues and gross profit.

Rare Disease and Brands revenues rose 41.2% to $182.3 million. Generics and Other rose 9.9% to $108.4 million.

What drove it: Cortrophin, ILUVIEN, generics and Harmony

Cortrophin Gel net revenues rose 36.1% to $138.7 million, up from $101.9 million. The company said growth was driven primarily by volume, from the gout expansion and progress in nephrology, neurology, rheumatology, ophthalmology and pulmonology. ANI said new gout patient cases doubled quarter-over-quarter and new prescribers rose by about 67%.

The company also said revenue conversion was slower than expected in both existing specialties and gout, because of capacity constraints in its specialty pharmacy network. It is expanding that network and its patient support capabilities. Demand indicators are therefore running ahead of recognised revenue, and the release frames the gap as an execution issue rather than a demand issue.

ILUVIEN net revenues rose 34.1% to $22.3 million on higher volumes and phasing of international shipments. Generic pharmaceutical products grew 10.7% to $104.5 million, which the company credited to demand for existing products and 2025 and 2026 launches. It has launched 16 new generics year-to-date. Brands slipped 6.5% to $10.0 million on lower demand for certain products.

A new line, Brand royalties and other revenues, contributed $11.5 million under the Harmony Agreement: $9.5 million of royalties on pitolisant-based products and $2.0 million tied to development milestones. There was no comparable revenue a year earlier, so this line accounts for part of the quarter's growth. The company said it will continue to earn low single digit royalties on pitolisant-based net sales.

Margins and costs

GAAP gross margin rose to 61.6% from 59.0%, and non-GAAP gross margin to 61.8% from 59.2%. The company cited a favourable product mix and Harmony revenue, partly offset by higher sales of products that carry a royalty payable.

Spending grew faster than R&D. GAAP SG&A rose 23.8% to $94.9 million, and non-GAAP SG&A rose 32.4% to $84.2 million, reflecting expansion of the Rare Disease team targeting acute gouty arthritis and broader growth activity. GAAP R&D rose 5.6% to $13.0 million, and non-GAAP R&D rose 4.7% to $12.3 million. Non-GAAP SG&A growth outpaced the 27.6% revenue growth, but gross margin gains and royalty income kept EBITDA growing faster still.

Guidance: a mixed revision

The headline describes a narrowed total revenue range of $1,085–$1,125 million, replacing $1,080–$1,140 million, which implies 23%–27% growth over 2025's $883 million. The Cortrophin range was cut to $480–$500 million from $520–$540 million, now implying 38%–44% growth on $348 million. ILUVIEN guidance rose to $80–$85 million from $78–$83 million.

Profit guidance moved up. Adjusted non-GAAP EBITDA is now $290–$300 million, from $285–$300 million, and adjusted non-GAAP diluted EPS is $9.37–$9.71, from $9.19–$9.69. The company also guided to a non-GAAP gross margin of 60.3%–61.0%, 21.5–21.8 million shares for EPS purposes, and a GAAP effective tax rate of 27%–29%. The CEO reiterated a target of about 40% Cortrophin growth in 2026.

Egetis bid and capital allocation

On November 5, ANI announced a recommended public offer for Egetis Therapeutics at SEK 11.25 per share, a 27% premium to the 60-day VWAP, and also for the company's convertible debt and warrants. The company put the value, including incentive programs, at about SEK 5.6 billion, or about $560 million. Egetis separately agreed to sell its Rare Pediatric Disease Priority Review Voucher for $190.0 million gross. Adjusted for estimated net PRV proceeds, ANI put the deal's enterprise value at about $434 million.

The prize is EMCITATE (tiratricol), described as the first and only approved treatment in the U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, with Orphan Drug exclusivity and patent protection into 2045. Egetis's board unanimously recommends the offer, and holders of about 42% of shares have undertaken to accept under certain conditions. Closing requires 90% acceptance and regulatory approvals. The offer is financed by cash on hand and new debt from JPMorgan Chase Bank, N.A., with an acceptance period expected from about November 20 to about December 18, 2026.

At September 30, ANI held $420.8 million in unrestricted cash, $304.5 million in net receivables and $616.9 million in principal debt, including its senior convertible notes. Year-to-date operating cash flow was $198.8 million. Under a $100.0 million buyback authorised in May, it has repurchased 275,635 shares for about $20.0 million through November 2.

What to watch

The key test is whether specialty pharmacy expansion converts gout demand into Cortrophin revenue fast enough to land within the lowered $480–$500 million range. The Egetis acceptance period, the 90% threshold and regulatory approvals come next, along with how the new debt affects leverage. Other items to watch are the durability of Harmony royalties, ILUVIEN follow-through after the SYNCHRONICITY NIU-PS data, and whether generics launches keep that segment's double-digit growth going.